1.Li G, Liu Y, Xie C, Zhou Q, Chen X. (2021) Characteristics of expedited programs on cancer drug approval in China. Nat Rev Drug Discov. 20(6):416. (IF = 64.80)
2.Li G, Qin Y, Xie C, Wu Y, Chen X. (2021) Trends in oncology drug innovation in China. Nat Rev Drug Discov. 20(1): 15-16. (IF = 64.80)
3.Li G, Liu X, Chen X. (2020) Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 17(10):589-590. (IF= 53.27)
4.Li G*, Yin C*, Zhou Y, et al. (2020) Digitalized Adaptation of Oncology Trials during and after COVID-19. Cancer Cell. 38(2):148-149. (IF = 26.60)
5.Zhou Q.Chen XY.Yang ZM,WU YL.The changing landscape of clinical trial and approval process in China.Nature Reviews Clinical Oncology.2017
6.2005-2010年我国化药抗肿瘤药申报和审批系统回顾与分析.中国药学杂志.45(22):1781-1785.
7.我国小分子靶向抗肿瘤药物申报现状浅析.中国新药杂志.20(17);1615-1619.
8.小分子靶向抗肿瘤药物临床研究策略探讨及案例分析.中国新药杂志.22(3);19-24.
9.2011.1-2013.7我国抗肿瘤药物申报和审批回顾分析.中国新药杂志.22(17);27-31.
10.我国抗肿瘤药加快审批5年历史回顾和思考.中国处方药杂志. (2010),2:11-13
11.关于甲磺酸伊马替尼口服制剂生物等效性研究设计的几点考虑；中国临床药理学杂志.2014.30（9）：840-843
12.Chen XY, Lu N, Nair R,et al.Decision Rules and Associated Sample Size Planning for Regional Approval Utilizing Multi-Regional Clinical Trials. Journal of Biopharmaceutical Statistics.2012 Sep;22(5):1001-18
13.Wang H, Chen XY, Wang BS,et al.The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatmen of acute promyelocytic leukemia: a meta-analysis. Leukemia Research.2011 Sep;35(9):1170-77
14.浅析紫杉醇新剂型开发需关注的问题，中国药学杂志，2010,45（22）
15.浅谈抗肿瘤药物的快速批准的风险/获益.中国药学杂志. 2010,45（22）
16.抗肿瘤药物I期临床研究设计考虑要点.中国临床药理学杂志，第25卷，第2期
17.抗肿瘤药物II期临床研究设计考虑要点.中国临床药理学杂志，第25卷，第3期.
18.抗肿瘤药物临床试验中安慰剂对照问题的探讨.中华肿瘤杂志，第31卷第5期
